{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:56:09Z","timestamp":1795042569695,"version":"4.10.2"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"7827","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1038\/s41586-020-2577-1","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T06:04:09Z","timestamp":1595570649000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":754,"title":["Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing"],"prefix":"10.1038","volume":"586","author":[{"given":"Laura","family":"Riva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-6718","authenticated-orcid":false,"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Martin-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-1042","authenticated-orcid":false,"given":"Lars","family":"Pache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-3510","authenticated-orcid":false,"given":"Sebastian","family":"Burgstaller-Muehlbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Teriete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell V.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper Fuk-Woo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Kwok-Man","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuoyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu-Trinh H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Rubanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveen","family":"Rathnasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3132","authenticated-orcid":false,"given":"Michael","family":"Schotsaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Miorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Dejosez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Zwaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Yung","family":"Sit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":false,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-0506","authenticated-orcid":false,"given":"Kris M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie E.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Lendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Glynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-503X","authenticated-orcid":false,"given":"Randy","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1241-2577","authenticated-orcid":false,"given":"Andrew D.","family":"Mesecar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8628-7019","authenticated-orcid":false,"given":"Ren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-4104","authenticated-orcid":false,"given":"Andrew I.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-1827","authenticated-orcid":false,"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-7982","authenticated-orcid":false,"given":"Arnab K.","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-1552","authenticated-orcid":false,"given":"Kwok-Yung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-7927","authenticated-orcid":false,"given":"Sumit K.","family":"Chanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"2577_CR1","first-page":"475","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Respir. Med."},{"key":"2577_CR2","doi-asserted-by":"publisher","first-page":"e0204532","DOI":"10.1371\/journal.pone.0204532","volume":"13","author":"D Sbrissa","year":"2018","unstructured":"Sbrissa, D., Naisan, G., Ikonomov, O. C. & Shisheva, A. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation. PLoS ONE 13, e0204532 (2018).","journal-title":"PLoS ONE"},{"key":"2577_CR3","first-page":"53","volume":"10","author":"A Billich","year":"2007","unstructured":"Billich, A. Drug evaluation: apilimod, an oral IL-12\/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10, 53\u201359 (2007).","journal-title":"IDrugs"},{"key":"2577_CR4","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.chembiol.2013.05.010","volume":"20","author":"X Cai","year":"2013","unstructured":"Cai, X. et al. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12\/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. Chem. Biol. 20, 912\u2013921 (2013).","journal-title":"Chem. Biol."},{"key":"2577_CR5","unstructured":"World_Health_Organization. Coronavirus Disease (COVID-19) Pandemic https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (2020)."},{"key":"2577_CR6","first-page":"00201","volume":"1\u20134","author":"WH Chen","year":"2020","unstructured":"Chen, W. H., Strych, U., Hotez, P. J. & Bottazzi, M. E. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 1\u20134, 00201-6 (2020).","journal-title":"Curr. Trop. Med. Rep."},{"key":"2577_CR7","unstructured":"Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C. & Di Napoli, R. in StatPearls (StatPearls, 2020)."},{"key":"2577_CR8","doi-asserted-by":"publisher","unstructured":"Chen, H. et al. First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.22.20034041 (2020).","DOI":"10.1101\/2020.03.22.20034041"},{"key":"2577_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"2577_CR10","unstructured":"US Food and Drug Administration. FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment (2020)."},{"key":"2577_CR11","doi-asserted-by":"publisher","unstructured":"Kujawski, S. A. et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Preprint at medRxiv\u00a0https:\/\/doi.org\/10.1101\/2020.03.09.20032896 (2020).","DOI":"10.1101\/2020.03.09.20032896"},{"key":"2577_CR12","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1810137115","volume":"115","author":"J Janes","year":"2018","unstructured":"Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl Acad. Sci. USA 115, 10750\u201310755 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR13","doi-asserted-by":"publisher","first-page":"104558","DOI":"10.1016\/j.antiviral.2019.104558","volume":"169","author":"YJ Kim","year":"2019","unstructured":"Kim, Y. J. et al. The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors. Antiviral Res. 169, 104558 (2019).","journal-title":"Antiviral Res."},{"key":"2577_CR14","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1504022112","volume":"112","author":"MB Harbut","year":"2015","unstructured":"Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA 112, 4453\u20134458 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR15","doi-asserted-by":"publisher","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","volume":"11","author":"MS Love","year":"2017","unstructured":"Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2577_CR16","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1073\/pnas.1702750114","volume":"114","author":"MJ Bollong","year":"2017","unstructured":"Bollong, M. J. et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc. Natl Acad. Sci. USA 114, 4679\u20134684 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/gm326","volume":"4","author":"YY Li","year":"2012","unstructured":"Li, Y. Y. & Jones, S. J. Drug repositioning for personalized medicine. Genome Med. 4, 27 (2012).","journal-title":"Genome Med."},{"key":"2577_CR18","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR19","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.3346\/jkms.2020.35.e84","volume":"35","author":"WB Park","year":"2020","unstructured":"Park, W. B. et al. Virus Isolation from the first patient with SARS-CoV-2 in Korea. J. Korean Med. Sci. 35, e84 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"2577_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/cid\/ciaa149","volume":"71","author":"KK To","year":"2020","unstructured":"To, K. K. et al. Consistent detection of 2019 novel coronavirus in saliva. Clin. Infect. Dis. 71, 841\u2013843 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"2577_CR21","doi-asserted-by":"publisher","first-page":"e0005540","DOI":"10.1371\/journal.pntd.0005540","volume":"11","author":"EA Nelson","year":"2017","unstructured":"Nelson, E. A. et al. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl. Trop. Dis. 11, e0005540 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2577_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2017.09.028","volume":"513","author":"S Qiu","year":"2018","unstructured":"Qiu, S. et al. Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology 513, 17\u201328 (2018).","journal-title":"Virology"},{"key":"2577_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","volume":"318","author":"N Yamamoto","year":"2004","unstructured":"Yamamoto, N. et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318, 719\u2013725 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2577_CR24","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","volume":"11","author":"C Shweta","year":"2020","unstructured":"Shweta, C., Yashpal S., M. & Shailly, T. Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Front. Immunol. 11, 1664 (2020).","journal-title":"Front. Immunol."},{"key":"2577_CR25","doi-asserted-by":"publisher","unstructured":"Xu, Z. et al. Nelfinavir is active against SARS-CoV-2 in Vero E6 cells. Preprint at https:\/\/doi.org\/10.26434\/chemrxiv.12039888.v1 (2020).","DOI":"10.26434\/chemrxiv.12039888.v1"},{"key":"2577_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00726-006-0403-1","volume":"33","author":"SQ Wang","year":"2007","unstructured":"Wang, S. Q. et al. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids 33, 129\u2013135 (2007).","journal-title":"Amino Acids"},{"key":"2577_CR27","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1128\/JVI.01001-12","volume":"86","author":"M Schneider","year":"2012","unstructured":"Schneider, M. et al. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J. Virol. 86, 10112 (2012).","journal-title":"J. Virol."},{"key":"2577_CR28","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"2577_CR30","doi-asserted-by":"publisher","unstructured":"Butler, D. J. et al. Host, viral, and environmental transcriptome profiles of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Preprint at bioRxiv\u00a0https:\/\/doi.org\/10.1101\/2020.04.20.048066 (2020).","DOI":"10.1101\/2020.04.20.048066"},{"key":"2577_CR31","doi-asserted-by":"publisher","unstructured":"Deprez, M. et al. A single-cell atlas of the human healthy airways. Am. J. Respir. Crit. Care Med. 34, https:\/\/doi.org\/10.1164\/rccm.201911-2199OC (2020).","DOI":"10.1164\/rccm.201911-2199OC"},{"key":"2577_CR32","first-page":"1057","volume":"23","author":"CY Kwan","year":"2002","unstructured":"Kwan, C. Y. & Achike, F. I. Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta Pharmacol. Sin. 23, 1057\u20131068 (2002).","journal-title":"Acta Pharmacol. Sin."},{"key":"2577_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1126\/science.1258758","volume":"347","author":"Y Sakurai","year":"2015","unstructured":"Sakurai, Y. et al. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 347, 995\u2013998 (2015).","journal-title":"Science"},{"key":"2577_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","volume":"5","author":"RM Inciardi","year":"2020","unstructured":"Inciardi, R. M. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 819\u2013824 (2020).","journal-title":"JAMA Cardiol."},{"key":"2577_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ipej.2020.04.003","volume":"20","author":"A Kapoor","year":"2020","unstructured":"Kapoor, A. et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: a scientific statement from the Indian Heart Rhythm Society. Indian Pacing Electrophysiol. J. 20, 117\u2013120 (2020).","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"2577_CR36","doi-asserted-by":"publisher","first-page":"E85","DOI":"10.3390\/microorganisms8010085","volume":"8","author":"S D\u2019Alessandro","year":"2020","unstructured":"D\u2019Alessandro, S. et al. The use of antimalarial drugs against viral infection. Microorganisms 8, E85 (2020).","journal-title":"Microorganisms"},{"key":"2577_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0166-3542(91)90005-C","volume":"16","author":"E Lucile White","year":"1991","unstructured":"Lucile White, E. et al. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 16, 257\u2013266 (1991).","journal-title":"Antiviral Res."},{"key":"2577_CR38","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1128\/AAC.36.12.2661","volume":"36","author":"S De Wit","year":"1992","unstructured":"De Wit, S. et al. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob. Agents Chemother. 36, 2661\u20132663 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2577_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/106002809102500513","volume":"25","author":"JC Garrelts","year":"1991","unstructured":"Garrelts, J. C. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP 25, 525\u2013531 (1991).","journal-title":"DICP"},{"key":"2577_CR40","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/jvi.64.2.941-943.1990","volume":"64","author":"L Bj\u00f6rck","year":"1990","unstructured":"Bj\u00f6rck, L., Grubb, A. & Kjell\u00e9n, L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J. Virol. 64, 941\u2013943 (1990).","journal-title":"J. Virol."},{"key":"2577_CR41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1586\/eri.12.104","volume":"10","author":"Y Zhou","year":"2012","unstructured":"Zhou, Y. & Simmons, G. Development of novel entry inhibitors targeting emerging viruses. Expert Rev. Anti Infect. Ther. 10, 1129\u20131138 (2012).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"2577_CR42","doi-asserted-by":"publisher","first-page":"8477","DOI":"10.1128\/JVI.00477-07","volume":"81","author":"Y Mori","year":"2007","unstructured":"Mori, Y. et al. Processing of capsid protein by cathepsin L plays a crucial role in replication of Japanese encephalitis virus in neural and macrophage cells. J. Virol. 81, 8477\u20138487 (2007).","journal-title":"J. Virol."},{"key":"2577_CR43","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"G Simmons","year":"2005","unstructured":"Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876\u201311881 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR44","doi-asserted-by":"publisher","first-page":"e1923","DOI":"10.1371\/journal.pntd.0001923","volume":"6","author":"A Marzi","year":"2012","unstructured":"Marzi, A., Reinheckel, T. & Feldmann, H. Cathepsin B & L are not required for ebola virus replication. PLoS Negl. Trop. Dis. 6, e1923 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2577_CR45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/jbmr.341","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell, R. et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 26, 1303\u20131312 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"2577_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/jbmr.2047","volume":"29","author":"R Eastell","year":"2014","unstructured":"Eastell, R. et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J. Bone Miner. Res. 29, 458\u2013466 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"2577_CR47","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1242\/jcs.03153","volume":"119","author":"AC Rutherford","year":"2006","unstructured":"Rutherford, A. C. et al. The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. J. Cell Sci. 119, 3944\u20133957 (2006).","journal-title":"J. Cell Sci."},{"key":"2577_CR48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","volume":"129","author":"S Gayle","year":"2017","unstructured":"Gayle, S. et al. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129, 1768\u20131778 (2017).","journal-title":"Blood"},{"key":"2577_CR49","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/jcb.29534","volume":"121","author":"F Sultana","year":"2020","unstructured":"Sultana, F. et al. Snx10 and PIKfyve are required for lysosome formation in osteoclasts. J. Cell. Biochem. 121, 2927\u20132937 (2020).","journal-title":"J. Cell. Biochem."},{"key":"2577_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1021\/acs.biochem.7b01160","volume":"57","author":"AN Matthew","year":"2018","unstructured":"Matthew, A. N., Kurt Yilmaz, N. & Schiffer, C. A. Mavyret: A pan-genotypic combination therapy for the treatment of hepatitis C infection. Biochemistry 57, 481\u2013482 (2018).","journal-title":"Biochemistry"},{"key":"2577_CR51","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S1473-3099(17)30486-3","volume":"17","author":"P Ferenci","year":"2017","unstructured":"Ferenci, P. New anti-HCV drug combinations: who will benefit? Lancet Infect. Dis. 17, 1008\u20131009 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"2577_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar, T. & Fordyce, M. Current status and prospects of HIV treatment. Curr. Opin. Virol. 18, 50\u201356 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"2577_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514\u2013523 (2020).","journal-title":"Lancet"},{"key":"2577_CR54","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14\u2013e23 (2020).","journal-title":"Lancet Microbe"},{"key":"2577_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08015-x","volume":"10","author":"S Yuan","year":"2019","unstructured":"Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10, 120 (2019).","journal-title":"Nat. Commun."},{"key":"2577_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"2577_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2577_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2577_CR59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"2577_CR60","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"2577_CR61","doi-asserted-by":"publisher","unstructured":"Anson, B. J. et al. Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs. Preprint at https:\/\/doi.org\/10.21203\/rs.3.rs-26344\/v1 (2020).","DOI":"10.21203\/rs.3.rs-26344\/v1"},{"key":"2577_CR62","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia, K. et al. A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119\u201316124 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2577_CR63","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM B\u00e1ez-Santos","year":"2014","unstructured":"B\u00e1ez-Santos, Y. M. et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 57, 2393\u20132412 (2014).","journal-title":"J. Med. Chem."},{"key":"2577_CR64","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1016\/j.bmcl.2008.08.082","volume":"18","author":"AK Ghosh","year":"2008","unstructured":"Ghosh, A. K. et al. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett. 18, 5684\u20135688 (2008).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2577_CR65","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"2577_CR66","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41596-019-0220-0","volume":"14","author":"A Jacob","year":"2019","unstructured":"Jacob, A. et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat. Protoc. 14, 3303\u20133332 (2019).","journal-title":"Nat. Protoc."},{"key":"2577_CR67","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1172\/JCI68793","volume":"123","author":"M Ghaedi","year":"2013","unstructured":"Ghaedi, M. et al. Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. J. Clin. Invest. 123, 4950\u20134962 (2013).","journal-title":"J. Clin. Invest."},{"key":"2577_CR68","doi-asserted-by":"crossref","unstructured":"Chu, H. et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin. Infect. Dis. ciaa410 (2020).","DOI":"10.1093\/cid\/ciaa410"}],"updated-by":[{"DOI":"10.1038\/s41586-024-07659-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2577-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T06:04:35Z","timestamp":1719036275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2577-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":68,"journal-issue":{"issue":"7827","published-print":{"date-parts":[[2020,10,1]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2577-1","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-024-07659-8","URL":"https:\/\/doi.org\/10.1038\/s41586-024-07659-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. A.G.-S. is inventor on patent applications on antiviral compounds against SARS-CoV-2 unrelated to this study and owned by the Icahn School of Medicine at Mount Sinai. A.K.C. and S.K.C. are inventors on a patent application on repurposed antiviral compounds for SARS-CoV-2 owned by Scripps Research and Sanford Burnham Prebys. US Patent Application Serial No. 63\/010630, entitled <i>Methods and Compositions for Antiviral Treatment<\/i> relates to aspects of this work and was filed on 15 April 2020. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}